Page 65 - Amgen News Today

Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.

Objectives To answer a national research priority by comparing the risk-benefit and costs associated with reverse total shoulder replacement (RTSR) and anatomical total shoulder replacement (TSR) in patients having elective primary shoulder replacement for osteoarthritis. Design Population based cohort study using data from the National Joint Registry and Hospital Episode Statistics for England. Setting Public hospitals and publicly funded procedures at private hospitals in England, 2012-20. Par...

Raymond James Financial Services Advisors Inc. increased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 467,736 shares of the medical research company’s stock after buying an additional 13,820 shares during […]

Northcape Wealth Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 11.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,961 shares of the medical research company’s stock after selling 265 shares during the quarter. Northcape […]

Citizens Business Bank cut its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 12.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,247 shares of the medical research company’s stock after selling 330 shares during the period. Citizens […]

Parthenon LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,177 shares of the medical research company’s stock after selling 50 shares during the quarter. Parthenon LLC’s […]

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript April 30, 2024 Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.00015, expectations were $-0.16. NAUT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International...

Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told...

New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD ...